PortfoliosLab logo
PortfoliosLab logo
Tools
Portfolios
Screeners
Discussions
SRTS vs. GENE
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between SRTS and GENE is 0.15, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

SRTS vs. GENE

Last updated Jun 3, 2025

Compare and contrast key facts about Sensus Healthcare, Inc. (SRTS) and Genetic Technologies Limited (GENE).

Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: SRTS or GENE.

Performance

SRTS vs. GENE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Sensus Healthcare, Inc. (SRTS) and Genetic Technologies Limited (GENE). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Fundamentals

Market Cap

SRTS:

$77.62M

GENE:

$3.71M

EPS

SRTS:

$0.11

GENE:

-$0.02

PEG Ratio

SRTS:

0.00

GENE:

0.00

PS Ratio

SRTS:

1.97

GENE:

0.38

PB Ratio

SRTS:

1.46

GENE:

3.29

Total Revenue (TTM)

SRTS:

$39.49M

GENE:

$4.80M

Gross Profit (TTM)

SRTS:

$22.12M

GENE:

$2.80M

EBITDA (TTM)

SRTS:

$2.79M

GENE:

-$5.47M

Returns By Period

SRTS

YTD

-31.79%

1M

9.01%

6M

-44.86%

1Y

-12.92%

3Y*

-18.53%

5Y*

9.49%

10Y*

N/A

GENE

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

3Y*

N/A

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Sensus Healthcare, Inc.

Genetic Technologies Limited

Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

SRTS vs. GENE — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.
SRTS
The Risk-Adjusted Performance Rank of SRTS is 3838
Overall Rank
The Sharpe Ratio Rank of SRTS is 4040
Sharpe Ratio Rank
The Sortino Ratio Rank of SRTS is 3939
Sortino Ratio Rank
The Omega Ratio Rank of SRTS is 3939
Omega Ratio Rank
The Calmar Ratio Rank of SRTS is 3636
Calmar Ratio Rank
The Martin Ratio Rank of SRTS is 3838
Martin Ratio Rank
GENE
The Risk-Adjusted Performance Rank of GENE is 77
Overall Rank
The Sharpe Ratio Rank of GENE is 44
Sharpe Ratio Rank
The Sortino Ratio Rank of GENE is 44
Sortino Ratio Rank
The Omega Ratio Rank of GENE is 33
Omega Ratio Rank
The Calmar Ratio Rank of GENE is 88
Calmar Ratio Rank
The Martin Ratio Rank of GENE is 1414
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

SRTS vs. GENE - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Sensus Healthcare, Inc. (SRTS) and Genetic Technologies Limited (GENE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

SRTS vs. GENE - Dividend Comparison

Neither SRTS nor GENE has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

SRTS vs. GENE - Drawdown Comparison

Loading data...

Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

SRTS vs. GENE - Volatility Comparison

Loading data...

Financials

SRTS vs. GENE - Financials Comparison

This section allows you to compare key financial metrics between Sensus Healthcare, Inc. and Genetic Technologies Limited. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.

Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities

0.002.00M4.00M6.00M8.00M10.00M12.00M14.00M20212022202320242025
8.34M
4.80M
(SRTS) Total Revenue
(GENE) Total Revenue
Values in USD except per share items